Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ATLCAR.CD30 cells |
| Trade Name | |
| Synonyms | CAR.CD30-expressing autologous T lymphocytes |
| Drug Descriptions |
ATLCAR.CD30 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets TNFRSF8 (CD30), which may induce lysis of TNFRSF8 (CD30)-positive tumor cells (PMID: 32701411, NCI Drug Dictionary). |
| DrugClasses | CD30 (TNFRSF8) Immune Cell Therapy 5 |
| CAS Registry Number | NA |
| NCIT ID | C116738 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ATLCAR.CD30 cells | ATLCAR.CD30 cells | 0 | 4 |
| ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | ATLCAR.CD30 cells ATLCAR.CD30.CCR4 cells | 0 | 1 |
| ATLCAR.CD30 cells + Bendamustine + Fludarabine | ATLCAR.CD30 cells Bendamustine Fludarabine | 0 | 0 |
| ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine | ATLCAR.CD30 cells Cyclophosphamide Fludarabine | 0 | 2 |
| ATLCAR.CD30 cells + Nivolumab | ATLCAR.CD30 cells Nivolumab | 0 | 1 |